Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Release Pirfenidone in Compensated Liver Cirrhosis
NCT06267794Phase 2Completed
- Start
- Jun 2015
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of pirfenidone in Liver cirrhosis (LC) (3 arms). Primary endpoints: Change in liver fibrosis at 24 months and Clinical side effects at 24 months. Started Jun 2015; status: completed.
02
Drugs
pirfenidone
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06267794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267794.